US FDA’s Makary Floats Vague ‘Plausible Mechanism’ Approval Pathway For Rare Diseases

 
• By Sarah Karlin-Smith

Ascertaining the novelty and benefits of Makary’s new drug approval idea – along with what it would take to implement it – requires more clarity on the types of studies he envisions being used to grant and confirm “plausible mechanism’ approvals.

black and white image of fog
Makary's vision for a new rare disease approval pathway appears to still be a bit foggy. (Shutterstock)

More from Approval Standards

More from Rare Diseases